The Future of Diagnostics Is Here

Existing sample-to-result PCR analyzers cost >$10K. Companies have spent billions trying to make them affordable. Now Sparrow has lowered manufacturing costs by up to 50X, opening a new billion-dollar market for consumer testing.

Our team previously co-invented the DNA collection kit used by 23andMe and Ancestry.com, commercialized the first point-of-care pharmacogenetic test, and achieved 3 FDA 510(k) clearances and a CLIA Waiver.

A Sparrow prototype sitting in the palm of someone's hand.

Affordable Polymerase Chain Reaction (PCR) will enable rapid testing for infectious diseases, food and water pathogens, genetic risks, and many other applications.

It is now possible because Sparrow has invented technologies that reduce manufacturing costs by up to 50X. This enables a new billion-dollar market for consumer testing.

Our team has co-invented the DNA collection kit used by 23andMe and Ancestry.com, commercialized the first point-of-care pharmacogenetic test, and achieved 3 FDA 510(k) clearances and a CLIA Waiver.

Meet Our Team

Paul Lem, M.D.

CEO

Biotech entrepreneur with 25 years in DNA diagnostics. Raised $37M. Co-inventor of DNA collection kit used by 23andMe, Ancestry.com, and millions of people.

Rachel Collier

VP Operations, Sales & Marketing

Founder of Third Door, a marketing agency specializing in eCommerce for multi-million-dollar brands. Former journalist and biotech Director of Communications.

Chris Harder, Ph.D.

Chief Technology Officer

Biotech executive with 20 years developing sample-to-result molecular and immunodiagnostic platforms. Led teams from concept through manufacturing and regulatory clearance, including first-in-class FDA 510(k) clearances and CLIA Waiver.

Our Vision

Better healthcare for billions of people — with a personal DNA analyzer in every home.

How It Will Work

1

Test yourself at home

2

Video call with a doctor

3

Electronic prescription if required

4

Home delivery of medication

Seeking Strategic Partners

Contact Us